ALTOIDA's proven technology offers the most precise identification of cognitive impairment and the early identification of an individual's path toward cognitive impairment (e.g. Alzheimer's disease and other dementias). Early identification is the trigger for prompt and effective mitigation. ALTOIDA's scoring products and services enable an unmatched level of data acuity in making a quantifiable assessment of an individual's cognitive and functional capabilities with ongoing monitoring and progression tracking. ALTOIDA's products and services are backed by peer-reviewed publications, multinational clinical trials and an expert team of scientists, clinicians and informaticists.